← All indications
Raynaud Disease
An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress.
Subtype terms (1)
More specific conditions that are subtypes of Raynaud Disease in the MeSH hierarchy.
- CREST Syndrome
2 drugs (1 approved, 1 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (5)
Phase 3 trials (13)
Phase 2 trials (7)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (23)
- Allergan
- Dong-A Pharmaceutical
- MediQuest Therapeutics
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Center for Research Resources (NCRR)
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pittsburgh
- University of Washington
- Johns Hopkins University
- Ochsner Health System
- Postgraduate Institute of Medical Education and Research
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
- Seoul National University
- University of Cologne
- India Army
- University of Sao Paulo
- Institute of Post Graduate Medical Education & Research
- University of Western Ontario
- Clinical Trials & Surveys Corp
- University of Grenoble
- Assistance Publique - Hôpitaux de Paris
- Civi Biopharma, Inc.
- Eicos Sciences, Inc.
Organization Involved with Phase 2 Indications (15)
Organization Involved with Phase 1 Indications (5)
Organization Involved with Other Experimental Indications (11)